Mutations only arise *after* treatment. Same as with BCR ABL drugs.
This is far less definitive than your statement implies.
"Evidence has emerged suggesting that cells bearing the T315I mutation may be present *early* in the disease and undergo expansion following elimination of their drug-sensitive counterparts."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.